| abstract |
This invention provides discrete oral dosage forms, typically tablets or capsules, containing (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol or a physiologically acceptable salt or solvate thereof, or a solvate of said salt, and an effective stabilizing amount of alginic acid. These dosage forms are useful for preventing or treating attention deficit hyperkinetic disorder or depression, or in the treatment of addiction to nicotine-containing products, especially tobacco-containing products, such as aiding in smoking cessation. |